Holly Allen, MS,CCC-SLP in Barlow, KY - Speech-Language Pathologist

Holly Allen, MS,CCC-SLP is a Speech-language Pathologist based in Barlow, Kentucky. Holly Allen is licensed to practice in Kentucky (license number KY2093) and her current practice location is 2529 Hazelwood Rd, Barlow, Kentucky. She can be reached at her office (for appointments etc.) via phone at (270) 559-3474.

NPI number for Holly Allen is 1376931006 and her current mailing address is 2529 Hazelwood Rd, Barlow, Kentucky. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1376931006.

Contact Information

	Holly Allen, MS,CCC-SLP
	2529 Hazelwood Rd, Barlow, KY 42024-9722
	(270) 559-3474
	Not Available

Healthcare Provider's Profile

Full Name	Holly Allen
Gender	Female
Speciality	Speech-language Pathologist
Location	2529 Hazelwood Rd, Barlow, Kentucky
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1376931006
Provider Enumeration Date: 01/05/2015
Last Update Date: 01/05/2015

Medical Identifiers

Medical identifiers for Holly Allen such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1376931006	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
235Z00000X	Speech-language Pathologist	KY2093 (Kentucky)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Holly Allen is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Holly Allen, MS,CCC-SLP 2529 Hazelwood Rd, Barlow, KY 42024-9722 Ph: (270) 559-3474	Holly Allen, MS,CCC-SLP 2529 Hazelwood Rd, Barlow, KY 42024-9722 Ph: (270) 559-3474

News Archive

Salix Pharmaceuticals to settle patent litigation of Novel's generic version of MOVIPREP

Salix Pharmaceuticals, Ltd. today announced that Salix and Norgine B. V. have entered into an agreement with Novel Laboratories, Inc. to settle patent litigation currently pending in the U.S. District Court for the District of New Jersey (Civil Action No. 3:08-02311 (FLW)(TJB)) regarding Novel's proposed generic version of MOVIPREP.

Avioq receives premarket approval from FDA for Avioq HIV-1 Microelisa System

Avioq, Inc. announced it has received premarket approval from the U.S. Food and Drug Administration (FDA) for the Avioq HIV-1 Microelisa System.

Allergan announces U.S. availability of SAPHRIS 2.5 mg tablets for children with bipolar I disorder

Allergan plc today announced that SAPHRIS (asenapine) 2.5 mg sublingual (placed under the tongue) black-cherry flavored tablets are available in pharmacies throughout the U.S. In March 2015, the U.S. Food and Drug Administration approved SAPHRIS for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients (ages 10 – 17).

New study: Periodontal therapy can help reduce medical costs for patients with diabetes

The results from a new CIGNA study support that there is a potential association between treated periodontal disease and reduced medical costs for patients with diabetes.

Holly Allen, MS,CCC-SLP - Speech-Language Pathologist in Barlow, KY